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ABSTRACT: As the coronavirus disease 2019 (COVID-19) pandemic unfolds, neurological signs and symptoms reflect the
involvement of targets beyond the primary lung effects. The etiological agent of COVID-19, the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), exhibits neurotropism for central and peripheral nervous systems. Various infective mechanisms and
paths can be exploited by the virus to reach the central nervous system, some of which bypass the blood−brain barrier; others alter
its integrity. Numerous studies have established beyond doubt that the membrane-bound metalloprotease angiotensin-converting
enzyme 2 (ACE2) performs the role of SARS-CoV-2 host-cell receptor. Histochemical studies and more recently transcriptomics of
mRNA have dissected the cellular localization of the ACE2 enzyme in various tissues, including the central nervous system.
Epithelial cells lining the nasal mucosae, the upper respiratory tract, and the oral cavity, bronchoalveolar cells type II in the
pulmonary parenchyma, and intestinal enterocytes display ACE2 binding sites at their cell surfaces, making these epithelial mucosae
the most likely viral entry points. Neuronal and glial cells and endothelial cells in the central nervous system also express ACE2. This
short review analyzes the known entry points and routes followed by the SARS-CoV-2 to reach the central nervous system and
postulates new hypothetical pathways stemming from the enterocytes lining the intestinal lumen.
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■ INTRODUCTION
The Coronaviridae are a family of enveloped viruses carrying
between 26 and 32 kilobases of single-stranded, positive-sense
RNA, the largest so far detected for an RNA virus.1,2
Coronaviruses (CoVs) infect a wide range of avian and
mammalian species. A first set of human CoVs (HCoV-OC43,
HCoV-293, HCoV-NL63, and HKU1-CoV) generally causes
mild and self-limiting respiratory diseases. A second set of
HCoVs are more pathogenic and include the etiological agents
of the two epidemics occurring earlier this century, namely, the
severe acute respiratory syndrome (SARS-CoV) and theMiddle
East respiratory syndrome (MERS-CoV) viruses. The ongoing
outbreak of coronavirus disease 2019 (COVID-19) is caused by
the recently discovered seventh human CoV, the severe acute
respiratory syndrome coronavirus 2 virus (SARS-CoV-2).
Various neurotropic viruses exert pathogenic effects on the
peripheral and central (CNS) nervous systems. To reach these
targets, viruses use different strategies adapted in the course of
evolution to exploit cell-surface molecules normally fulfilling
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completely different functions in the cell, to serve as binding
partners. Binding of viruses to these adapted molecules, usually
transmembrane enzymes, is the first step in viral infection. CoVs
have perfected these strategies using metalloproteases as
recognition molecules and other membrane-bound enzymes
such as the transmembrane serine protease 2 (TMPRSS2) for
activation of a key viral protein during the subsequent step of the
infection process. SARS-CoV-2 engages its spike S glycoprotein,
interacting in sequential order with these two proteins before
fusing with the host membrane.3
Other viruses such as the mouse hepatitis virus (MHV) beta-
CoV rely on the S protein N-term domain to bind to the
carcinoembryonic antigen-related cell adhesion molecule 1
(CEACAM1).4 A zinc metalloprotease, aminopeptidase N
(APN, CD13), serves as a host-cell receptor molecule for
human H229E-CoV, transmissible gastroenteritis virus, porcine
epidemic diarrhea, and feline infectious peritonitis virus. The
enzyme dipeptidyl-peptidase 4 (DPP4), also known as a cluster
of differentiation 26 (CD26), present in the apical surface of
unciliated bronchial epithelial cells, acts as the receptor for
MERS-CoV.5 MERS-CoV can also infect human pulmonary
epithelial cells through highly specific but low affinity
interactions with sialic acid residues present in host cell-surface
glycoproteins6 using a different region of its spike protein S.7
During the first weeks of the pandemic, individuals admitted
to hospital presented the typical initial symptomatology of lower
respiratory tract infection, associated with fever, fatigue with or
without myalgia, sore throat, shortness of breath, dry cough, and
in moderate-to-severe cases, dyspnea; rhinorrhea was seldom
observed.8,9 Fever was by far the most frequent sign.9,10
Computer tomography revealed ground-glass opacity in roughly
50% of hospitalized patients with lower respiratory tract
symptoms.10−12 As the number of cases rose worldwide, the
spectrum of symptoms reported for COVID-19 patients
widened (see reviews, e.g., in refs 13 and 14). The degree of
severity covered a wide range of clinical presentations that were
not restricted to the respiratory tract or the pulmonary
symptoms and signs. Patients with comorbidities such as
hypertension, cardiovascular diseases, or diabetes were found
to be more prone to develop severe forms of the disease and
multiple organ dysfunction.12,15,16
Early reports of sensory dysfunction such as hyposmia17,18
and other forms of dysosmias and dysgeusias18−24 were the
initial indications of nervous system involvement in COVID-19.
These sensory dysfunctions were also observed in patients who
recovered from COVID-19 and at later stages presented
anosmia, rarely hyposmia.25 Life-threatening neurological
presentations, such as stroke, were and remain exceptional
findings.26
Reports of neurological complications of COVID-19 became
more frequent as the number of hospitalized patients increased.
These included cases of peripheral neuropathies and neuro-
muscular pathologies such as rhabdomyolysis or Guillain-Barre ́
syndrome, to severe CNS complications such as encephalitis,
encephalopathy, necrotizing hemorrhagic encephalopathy,
some forms of epilepsy, or stroke (reviewed in refs 27−30).
The incidence of some of these neurological clinical pictures
appears to be relatively high: Mao and co-workers18 reported
that 36.4% of COVID-19 patients showed neurological
symptoms, with specific but mild symptoms such as dysgeusias
or dysosmias early on in the course of the disease. The reader is
referred to several other reviews on the clinical and neurological
manifestations of COVID-19 that have recently ap-
peared.14,24,29,31−39
The occurrence of neurological manifestations in a viral
infectious disease such as COVID-19 poses several interesting
issues on the pathogenesis of this clinical entity. Since the first
step of the viral infectionbinding to a target host cell-surface
moleculemimics a ligand−receptor interaction, the question
arises as to which tissues are the ports of entry and in which cells
the receptors are located; second, which are the routes followed
by the virions surpassing these first barriers to reach the CNS
and produce neurological manifestations. This short review
addresses these issues: the possible neural or non-neural routes
and mechanisms that the SARS-CoV-2 virus could follow to
reach and infect the CNS, the presence and distribution of the
counterpart cell-host receptor for the SARS-CoV-2 (the
membrane-bound metalloprotease angiotensin-converting en-
zyme 2, ACE2), as analyzed by immunohistochemical or more
recently by mRNA transcriptomics, and finally a discussion of
hypothetical new routes that the virus could follow to reach the
CNS from its enteric entry point.
■ THE NASAL MUCOSA
The nasal cavity can be divided into three regions: the squamous
region and the respiratory and the sensory olfactory mucosae.
Figure 1.Nasal mucosae (left panel) and cellular composition of the olfactory and respiratory regions of the nasal mucosae (right panel). Color code
depicts the various cellular components, some of which may be used by SARS-CoV-2 to produce the primary infection and serve as a starting point to
reach the brain by neural or non-neural paths.
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The squamous region, the most external portion, is lined with
stratified keratinized squamous epithelium and is therefore
unlikely to be a site of viral infection under normal conditions.
Most of the nasal cavity corresponds to the respiratory region,
which is no longer a squamous multilayered epithelium but a
non-keratinized pseudostratified epithelium lined with basal
cells, ciliated and nonciliated columnar cells, secretory cells, and
goblet cells (Figure 1).40,41 Basal cells are in contact with the
basal membrane and have the inherent capacity to differentiate
into the other types in the nasal mucosa. Columnar cells possess
cilia and numerous microvilli at their apical surface and are
“sealed” with tight junctions at the border between their apical
zone and the uppermost section of the basolateral membrane.
The goblet cells secrete mucin, a key component of the mucus
layer. The respiratory region of the nasal cavity (Figure 1) is
innervated by the trigeminal nerve, which stems from the pons in
the brainstem42 and constitutes therefore a potential pathway
for the centripetal routing of an infective agent.
The olfactory region is located cephalically to the respiratory
region, in and beneath the roof of each nasal cavity, and is lined
with a specialized type of pseudostratified monolayer of
epithelial cells, harboring (a) olfactory sensory (receptor)
neurons, the first cells in the chain of olfactory sensory function,
with an exquisite variety of odor receptors expressed at their
apical (dendritic) cilia; (b) sustentacular (“supporting”) cells,
which keep the electrolytic balance required for olfactory
function, and as we will see constitute a possible gateway for
SARS-CoV-2 entry into the CNS; (c) microvillar cells as in the
respiratory region; (d) globose basal cells, which are stem cells
that differentiate into olfactory neurons to replace those
physiologically lost by aging, and (e) horizontal basal cells,
also of stem lineage, that actively generate multiple mature cells
in the olfactory epithelium, including the olfactory neuronal and
non-neuronal cells.43 Olfactory stem cells generate support cells
in the absence of cell division.44 The Bowman gland cells also
contribute to mucus secretion and homeostatic electrolyte
balance. Two major local effects of infection with human CoVs
on the nasal mucosa are the disruption of the ciliated epithelium
and ciliary dyskinesia, which affect mucociliary clearance and
contribute to the pulmonary disease.45
Recent single-cell RNA-Seq profiling analysis explored the
cellular composition, distribution, and transcriptional hetero-
geneity of normal human airway mucosa obtained by
bronchoscopic aspiration along the respiratory tract.46 This
resulted in an atlas (in the framework of the Human Cell Atlas,
https://www.humancellatlas.org/) showing a rather stable cell
type-specific gene expression all along the respiratory tract, but
exhibiting differential gene expression between otherwise
identical cell types from the nasal epithelium down to the
12th division of the tracheobronchial airway epithelium. In
addition, rare pulmonary neuroendocrine and brush cells and
ionocytes were found to derive from a common population of
precursor cells.46 The same authors explored in more detail the
differentiation of the mucociliary system in another single-cell
RNA-Seq transcriptomics study on cell cultures of human
mucosal cells.47 They found that goblet cells can be precursors of
multiciliated cells and that a subgroup of multiciliated cells
expressed the DEUP1 gene, a hallmark of massive centriole
amplification at these cells.
Some of the RNA-Seq studies indicate that the trans-
membrane proteases purported to be the cell-host receptors
for SARS-CoV-2 (see section below) are present in the
respiratory epithelial cells,3,48 whereas other studies show only
low level expression of these two proteases in the human
mucosal epithelial cells.49 This latter study identified 194
nonolfactory genes. The human genome contains 857 olfactory
receptor genes, of which roughly half are pseudogenes.
■ HUMAN VIRAL INFECTIONS OF THE NASAL
MUCOSA
Rhinitis and rhinosinusitis (sometimes with concomitant
polyposis), the predominant causes of olfactory impairment,
were already the most common chronic medical conditions
almost two decades ago, affecting in the USA alone about 32
million individuals, with permanent dysfunction predominantly
observed in the elderly.50 Acute viral rhinitis is the most
common cause of nontraumatic olfactory dysfunction; traumatic
causes are usually associated with head injuries causing tearing
or severing of olfactory neuron axons at the cribriform plate.
CoVs have been known to be infective agents of the nasal
mucosa for many decades, and verification was provided by early
experimental clinical studies. An example of this was the
reported elevated olfactory thresholds to 1-butanol among
volunteers who had been inoculated with one of the human
CoVs responsible for the common cold, HCoV-229E, and who
developed viral rhinitis relative to uninfected control subjects.51
Immunohistochemical studies have documented the alter-
ations in olfactory epithelial cells as sequelae of various types of
olfactory disorders following viral infections.52 The disability of
the upper respiratory tract associated with viral diseases gave rise
to a nosological entity, the postviral olfactory dysfunction
(PVOD); rhinoviruses, belonging to a genus of the Picornavir-
idae family and etiological agent among other viruses of the
common cold, are the most frequently isolated species, together
with CoVs, parainfluenza virus Epstein−Barr virus, adenovi-
ruses, enteroviruses, and respiratory syncytial viruses.53,54
Unlike these other viral rhinitides, the olfactory disability
observed in several clinical cases of COVID-19 does not usually
present rhinorrhea.20
■ CELLULAR TOPOGRAPHY OF RECEPTOR
MOLECULES FOR SARS-COV-2
Both SARS-CoV and SARS-CoV-2 exhibit marked tropism for
cells that harbor ACE2 at their plasmalemma, predominantly in
cells lining the oral and nasal cavities, upper respiratory tract, and
bronchoalveolar cells.55−57 Other receptors and coreceptor have
been postulated for SARS-CoV-2, such as CD147, also known as
Basigin or EMMPRIN, a transmembrane glycoprotein belong-
ing to the immunoglobulin superfamily.58 The transmembrane
serine proteases TMRSS2 and TMPRSS4 play a key role in
facilitating SARS-CoV-2 spike fusogenic activity on the host-cell
plasmamembrane, thus promoting the entry of the virus into the
cell,59 acting as “co-receptors” of ACE2.
Why have the nasal and oral mucosae acquired such relevance
in the context of COVID-19? At first glance, the contribution of
the two mucosae does not appear to lend support to their
possible role as viral reservoirs or massive sources of virions for
secondary infections. The nasal mucosae cover a surface of
∼150−160 cm2 (refs 40 and 60) and the oral cavity ∼215 cm2
(ref 61). The tongue expresses much higher amounts of ACE2
than the rest of the oral mucosa.56 In contrast, the total surface of
the intestinal mucosae (∼ 250 m2) or the upper respiratory tract
and the pulmonary alveolar region (118± 22m2 and 91± 18m2
in male and female individuals, respectively (Colebatch and Ng
1992)) are several orders of magnitude larger. Despite their
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relatively small surface, however, the nasal mucosae are of
particular importance because of their anatomical vicinity and
connections to the forebrain via the shortest of the cranial
nerves, the olfactory nerve.
The oral and nasal mucosae became relevant within the
context of the current pandemic following the observation of
clinical symptoms in COVID-19 associated with alterations in
the sensory systems of odor and taste, namely, dysosmias and
disgeusias.21,23,32 Knowledge of the distribution, absolute
number, and surface density of ACE2 viral receptor molecules
constitutes the first step toward establishing which cells exhibit
higher tropism for the viruses, are at greater risk of being
infected, and ultimately offer better chances for the viruses to use
them as entry points and routes to infecting other organs. The
tropism of the virus for certain cells over others also points not
only to them being acute targets for gaining entry into the
organism but also to their preferential exploitation as reservoirs,
as is the case with viruses that reemerge after long latencies. It
became important to discriminate whether these sensory
disturbances were a manifestation of a peripheral affectation of
the mucosae or a more serious neurological complication
involving the CNS. It was soon hypothesized that the olfactory
epithelium was the likely site of enhanced binding of SARS-
CoV-2, correlating this with the clinical olfactory dysfunction
observed in some COVID-19 patients, and the possibility was
suggested that the olfactory receptor neurons were the site of
origin of subsequent brain infection by the virus.62 Although the
early clinical data did not reveal a high incidence of severe
neurological complications in COVID-19, such as encephalo-
pathies or encephalitis,27,29 as the pandemic progressed over
time so did the casuistic involving the CNS.35
In parallel, experimental data began to emerge. Using a mouse
animal model, the predominant expression of ACE2 and
TMPRSS2 in the sustentacular cells of the olfactory epithelium
was demonstrated, thus suggesting that non-neuronal cells could
be responsible for the olfactory impairment.63 This was followed
by experimental demonstration that this was indeed the case:
massive damage of the olfactory epithelium was observed as
early as 2 days after nasal instillation of SARS-CoV-2 in golden
Syrian hamsters, with a substantial loss of cilia.64 The injured
cells were primarily the sustentacular cells.
As is the case with other cell-surface receptors, the distribution
and local density of ACE2 play a determinant role in the efficacy
of the binding step, be it ligand or virion, especially if ACE2
forms supramolecular aggregates that enhance the chances of
successful hits by the viral particle. Clustered ACE2molecules in
complex withMERS-CoV have been experimentally observed.65
Transcriptomic RNA-Seq analyses have shown that respira-
tory epithelial cells express ACE2 and TMPRSS2, the trans-
membrane serine protease SS 2 required for viral S protein
activation, albeit in variable amounts.3,48,49,59 The situation
differs in the olfactory region of the nasal mucosa, where only
TMPRSS2 appears to be present in both immature olfactory
neurons and non-neuronal cells in mice.66,67 In the latter study,
essentially all (98.9%) olfactory receptor genes were found to be
expressed in mature olfactory sensory neurons.
An RNA-Seq study found that goblet, basal, and ciliated cells
in the respiratory region of the nasal mucosa (Figure 1) express
high levels of the ACE2 and TMPRSS2 genes, together with
genes involved in innate immune functions and antiviral genes
(IDO1, IRAK3, NOS2, TNFSF10, OAS1, andMX1), suggesting
that these cell types could serve as entry points for SARS-CoV-2
infection and, not less importantly, viral reservoirs for
dissemination. Highest expression was found in goblet
(especially goblet 2 cells) and ciliated cells.68 The TMPRSS2
gene was only expressed in a subset of ACE2+ cells, suggesting
that the virus might use alternative pathways.68 TMPRSS2- cells
could instead use cathepsin B/L as a substitute membrane-
bound enzyme co-opted as receptor.3 Also applying bulk and
single-cell RNA-Seq methods, another study analyzed the cell
types present in the olfactory epithelium and olfactory bulb that
expressed the ACE2 and TMPRSS2 genes.69 Remarkably,
neither olfactory sensory neurons nor olfactory bulb neurons
express the SARS-CoV-2 host-cell receptors. Instead, the gene
coding for the ACE2 protein in the olfactory bulb were only
found in the vascular pericytes, the cells involved in maintaining
blood pressure regulation and the integrity of the BBB, as well as
in olfactory support cells and stem cells. TMPRSS2 was not
expressed in the olfactory bulb. The authors surmise that it is the
infection of the non-neuronal cells that contributes to the
olfactory dysfunction of COVID-19 patients. This opens up the
possibility that once the epithelial cell barrier is surpassed, the
virions enter local capillaries in the nasal submucosa and make
their way into the capillary lumen via the pericytes, rich in ACE2,
and the endothelial cell, also rich in ACE2,70 to reach general
circulation.
An in vitro study using organoids of human airway epithelium
found that SARS-CoV-2 readily infected ciliated cells but not
goblet cells.71 These findings contrast with those of another
study in which ACE2+TMPRSS2+ gene coexpressing cells were
found in nasal goblet secretory cells, AT2 alveolar cells, and ileal
absorptive enterocytes. By treating primary human upper airway
basal cells with distinct types of inflammatory cytokines, or
infecting cells with human influenza virus, the authors further
showed that the ACE2+ gene is stimulated by human interferon-
α.72 In one of the most comprehensive analyses to date, RNA-
Seq libraries compiled from ∼29 000 single cells from human
olfactory neuroepithelium found expression of ACE2 and
TMPRSS2 genes in sustentacular cells, and expression of the
ACE2 protein alone was observed in a subset of these cells.73
Olfactory sensory neurons showed little or no expression of the
two proteins.
A note of caution comes from a study drawing a comparison
between the transcriptomic mRNA profile and the immunocy-
tochemical protein expression profile of ACE2 in more than 150
cell types. The highest expression of ACE2 was observed in the
intestinal tract, with brain showing no expression, and low or no
expression in a subset of cells in the respiratory system.57 The
study also reanalyzed the transcriptomics profiles of 9 other
studies in the literature, confirming both the high expression
levels (>60%) in ileal enterocytes and the enrichment of ACE2 in
AT2 cells in the pulmonary parenchyma.
Heterogeneity in the expression of ACE2missense mutants in
different ethnic groups was recently reported,74 providing
another source of variability in risk among COVID-19 patients
and the different susceptibility of certain organs to become
targets of the disease. RNA-Seq data extracted frommore than 4
million human cells by the Human Cell Atlas project identified
subsets of respiratory epithelial cells in the nasal passages,
airways, and alveoli coexpressing both ACE2 and the protease
(ACE2+TMPRSS2+).75 Coexpression in enterocytes, corneal
epithelial cells, cardiomyocytes, heart pericytes, olfactory
sustentacular cells, and renal epithelial cells may provide
higher-susceptibility targets for the virus. Furthermore, some
of these ACE2+TMPRSS2+ gene-expressing cells were found to
share a gene expression program that mediates viral entry and
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immune functions, like genes coding for IL-6, its receptor IL-6R,
and coreceptor IL-1R.75 In children, T2 inflammation and
interferon response to respiratory viruses upregulate the ACE2
and TMPRSS2 genes through other interleukins such as IL-13.76
However, interferon differentially increases only ACE2 in
asthmatic patients,77 highlighting the variability of interleukin
regulation of gene expression.
A recent immunocytochemical study found expression of
ACE2 in the motile cilia of the respiratory tract epithelia and
demonstrated that among various factors, comorbidities modify
the expression of the enzyme.78 One such comorbidity is
smoking, a habit that alters the morphology of cilia and
mucociliary clearance.79 Using reverse genetics, a green
fluorescent protein (GFP)-reporter virus was used as a probe
to investigate SARS-CoV-2 pathogenesis along the respiratory
tract. The highest expression was found in ciliated epithelial cells
of the nasal mucosa with decreasing expression along the lower
tract, paralleled by a similar pattern in viral infectivity in cell
cultures; in pulmonary tissue, ciliated cells and AT2 pneumo-
cytes showed expression, though much lower than in nasal
mucosa.80 Mice placed for 5 months under regimes of exposure
to cigarette smoke showed a dose-dependent increase in
pulmonary ACE2 levels, up to∼80% higher in animals subjected
to the maximal dose; a similar dose-dependent expression was
observed in humans, with an associated expansion of the number
of ACE2-rich mucous-secreting goblet cells.81
One remarkable aspect of the COVID-19 pandemic is that
right from its outbreak it triggered a wide variety of studies
conducted at an accelerated pace and focused on different
aspects of the disease, from the clinical to the more basic
extremes of the research spectrum. The transcriptomics
approaches discussed in this section reflect the contribution of
the latter, with the converging expertise of high-throughput next
generation sequencing (NGS) RNA-Seq techniques, specialized
ad hoc software technology, in silico analyses of large library data
banks, and single-cell cytology approaches to map the static
cellular transcriptome. The implementation of these approaches
has led to the rapid identification of the phenotypic distribution
of the host-cell receptor of SARS-CoV-2, the metalloenzyme
ACE2, in epithelial mucosae, and the coreceptor protease
TMPRSS2. A most interesting outcome is the heterogeneous
distribution revealed by the single-cell analyses and not apparent
(or averaged) in population-level studies, depicting subsets of
epithelial cellular phenotypes. These transcriptional signatures
may prove important in understanding the susceptibility of
certain cells to infection, virion-mammalian cell interactions, the
characteristics of the virion replication cycle in different cell
types, and in devising prophylactic or therapeutic strategies for
this and other viral diseases.
■ ACE2 IN THE CNS
ACE2 is a key element in the anti-inflammatory and hypotensive
arm of the renin-angiotensin-aldosterone system (RAAS). An
endogenous RAAS is operative in the CNS.82−84 This system,
which has an important role in the brain, has two branches: the
vasoconstrictor and pro-inflammatory renin-angiotensin [1-9]-
angiotensin converting enzyme (ACE) branch and the vaso-
dilator and anti-inflammatory ACE2-angiotensin [1-7]-Mas
receptor arm. ACE2 enzymatically modifies the vasoconstrictor
peptides angiotensin II and angiotensin I into the vasodilator
peptides, Ang [1-7] and Ang [1-9], respectively. Angiotensin [1-
7] (Ang[1-7]) is the predominant form in various regions of the
brain, including the hypothalamus and amygdala, as well as in
Figure 2. Hypothetical alternative SARS-CoV-2 routes in addition to the ones originating in the nasal mucosa (Figure 1). These routes stem from a
common entry point: the enterocyte lining the intestinal lumen (bottom left corner of the diagram). Upon enterocyte or para-enterocyte (tight
junction) infection, the virus may gain access to (a) the submucosal capillary network of the portal vein system (red arrows at the left bottom of the
scheme) to reach the liver and subsequently the brain via a hematogenous route. (b) A second hematogenous route, following infection of inflammatory
cells in the submucosal connective tissue to eventually reach the CNS via a “Trojan horse” mechanism has been observed with some CoVs in other
human respiratory diseases.101 (c) I also suggest the possibility that SARS-CoV-2 may utilize a third neural route resulting from the infection of
submucosal plexus and/or myenteric plexus neurons to deliver virions into the CNS via a neuron-to-neuron track102 following the dorsal root ganglion
sensory neuron retrograde path (see main text).
ACS Chemical Neuroscience pubs.acs.org/chemneuro Review
https://dx.doi.org/10.1021/acschemneuro.0c00434
ACS Chem. Neurosci. 2020, 11, 2793−2803
2797
the medulla oblongata.85 Ang[1-7] inhibits hypothalamic
noradrenergic neurotransmission, reducing inflammation, oxi-
dative stress, and neuronal apoptosis (see literature meta-
analysis in ref 86).
Potential sites for SARS-CoV-2 recognition in brain can be
inferred from the ACE2 mRNA distribution in adult human
brain. ACE2 has been found to be highly expressed in the
substantia nigra, choroid plexus, ventricles, middle temporal
gyrus, posterior cingulate cortex, and olfactory bulb.70 The
protein is expressed in the cytoplasm of both neuronal and glial
cells of human brain, in sympathetic tracts of the brainstem, and
in the motor cortex.82 Transcriptomic analyses have found
ACE2 to be highly expressed in both excitatory and inhibitory
neurons, astrocytes, oligodendrocytes, and endothelial cells.70
Interestingly, ACE2 has also been found in the brainstem
cardiorespiratory nuclei,83,87 raising the possibility that the
direct SARS-CoV-2 attack on these centers is responsible for the
atypical form of the acute respiratory distress like-syndrome
(ARDS) that characterizes some terminal forms of the disease,
now redefined as ARDS-like syndrome in COVID-19 or
“CARDS”.88,89
The widespread distribution of the host-cell receptor for
SARS-CoV-2 in the CNS can be correlated with the
symptomatology of some of the neurological presentations
and/or complications of COVID-19. Data from autopsies are
still scarce. A most recent study of 32 COVID-19 autopsies
showed SARS-CoV-2 RNA in the respiratory and cardiovascular
regulatory centers in the medulla oblongata.90 Further data are
required to fully substantiate the direct attack on the CNS or its
involvement as a cause of death, although some cases of severe
encephalitis and encephalopathies as neurological complications
have been reported.91−93
■ ALTERNATIVE HYPOTHETICAL ROUTES THAT
SARS-COV-2 MAY FOLLOW TO REACH THE CNS
Using the nasal mucosae as its entry point and primary infection
site, SARS-CoV-2 can gain access to the brain parenchyma
following the various short-path neural or hematogenous routes
that link these mucosae to the anatomically adjacent forebrain
across the cribriform plate, as analyzed previously (Figure 1),
but additional viral entry points need be considered because of
their much larger areas, abundance of SARS-CoV-2 receptors
and coreceptors, and hence important virion replicative capacity.
These are the respiratory system (tract epithelium-to-capillary
or alveolar pneumocyte cell-to capillary) leading to virus passage
to the pulmonary/general circulation (which will not be dealt
with) and the gastrointestinal tract (Figure 2). In addition, I
discuss here hypothetical routes relating to the latter.
The intestinal (predominantly the small intestine) lumen
entry point is a monolayer of cylindrical epithelium with a
predominant cell phenotype, the enterocyte, covering a surface
close to 250 m2 in contrast to the ∼150 sq. cm of the nasal
mucosae. Virus infection proceeds at the apical surface of the
enterocyte, covered with microvilli that increase the absorptive
area (relative to a flat surface) ∼25 times and which
concomitantly amplifies the coverage with ACE2 receptor
molecules. The gene coding for this receptor,ACE2, is expressed
together with its coreceptor, TMPRSS2 in absorptive enter-
ocytes in human ileum72 together with TMPRSS4.59
Although SARS-CoV-2 internalization is still not fully
understood, other CoVs employ both endocytic and non-
endocytic mechanisms.94 MHV-2, for instance, is internalized by
a clathrin-mediated, Eps15-independent mechanism.95 SARS-
CoV-2 pseudovirions were recently shown to be internalized in
mammalian cells in vitro mainly by an endocytic mechanism
dependent on the protease cathepsin L, the lysosomal
downstream effector pore channel subtype 2 (TPC2), and
phosphatidylinositol-3,5-bisphosphate (PI(3,5)P2). The inosi-
tol lipid is synthesized by phosphatidylinositol 3-phosphate 5-
kinase (PIKfyve) in the early endosome, making this enzyme a
potential drug target for SARS-CoV-2 inhibition.48 An example
of a nonendocytic internalization mechanism is the passage of
virions between epithelial intercellular junctions.96
Once inside the enterocyte, the virus undergoes its replicative
cycle, and virion shedding across the enterocyte basal membrane
puts SARS-CoV-2 in contact with the rich and extensive
capillary network in the intestinal villi, only tens of microns from
the epithelial lining. Pericytes69 and endothelial cells, rich in
ACE2,70 offer new targets for the virion to reach the general
circulation via the hepatic portal system. This first hematogenous
route (a) is schematically portrayed in Figure 2. Evidence of
gastrointestinal disease is observed in 45% of COVID-19
necropsies.97 Adverse pre-existing endothelial conditions as
observed in several comorbidities in COVID-19 patients and/or
the effects of hyperimmune response syndrome on the
endothelial cell bed (cytokine release syndrome)98 may lay
the ground for capillary dysregulation supporting SARS-CoV-2
infection of the CNS after defeating a weakened BBB (Figure 2).
(b) Having reached the general circulation, SARS-CoV-2 may
also employ a second hematogenous routethe so-called
“Trojan horse” mechanismknown to be operative for several
microbial agents that infect the brain parenchyma,99 involving
extravasation of inflammatory phagocytic cells (leukocytes,
mostly monocytes and lymphocytes) into the meninges and
cerebrospinal fluid. This route would follow essentially the same
course as (a) above, except that it is a facilitated path, because
the capillary network in the outer meningeal space is devoid of
tight junctions. Furthermore, the meningeal lymphatic system
serving the CNS provides additional pathways from the
meningeal space to the brain parenchyma.100
(c) A third hypothetical neural route is that SARS-CoV-2
virions, after surpassing the enteric epithelial wall, could directly
infect neuronal cells of the submucosal or myenteric plexus and
through neuron-to-neuron transport102 and also the sympa-
thetic neuron of the dorsal root ganglion, as shown in Figure 2.
The viruses would then be able to centripetally reach the CNS
via the spinal cord, subsequently propagating either from neuron
to neuron synaptically or crossing the blood−cerebrospinal fluid
barrier and the choroid plexus, again bypassing the BBB using
the Trojan horse mechanism described above. Other neuro-
tropic viruses such as varicella zoster virus103 employ the DRG
sympathetic neuron bidirectionally to reach the CNS and the
peripheral sensory nerve endings. Bulk RNA transcriptomic
analyses have shown expression of the ACE2 gene in human
DRG neuronal cells104.105 Human DRG neurons express
MRGPRD and Nppb genes, the former of which is selectively
expressed in a subset of nociceptive receptors that forms
peripheral nerve endings in colon106 or meninges107 together
with the ACE2 gene.105 The painful peripheral neuropathies
observed in some COVID-19 patients could be associated with
interferon-1-induced hyperexcitability of DRG neurons result-
ing from viral infection.108 A similar exacerbated immune
response may also account for the peripheral vascular
inflammatory reactions observed in the multisystem Kawasaki-
like syndrome that affects some COVID-19 patients,109,110
particularly children. Dermatological manifestations of COVID-
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19 such as maculopapular exanthem present in ∼36% of
patients111 could also progress from the DRG neuron to the skin
in an anterograde fashion, as schematically shown in the bottom
right portion of Figure 2 (red arrow). For all these reasons, the
intestinal mucosa is proposed to be a preferred entry point,
major viral reservoir, and favored starting point for neurotropic
routes.
■ CONCLUDING REMARKS
The distribution and abundance of the ACE2 molecule in
different cells dictate the tropism of the virus and probably the
viral load in each target surface. In the first part of the review, I
analyzed the “cellular cartography” of the receptor molecule in
the various cell phenotypes of the nasal and intestinal mucosae
based on RNA-Seq analysis. Although there is as yet no universal
consensus, the topography and abundance of ACE2 and SARS-
CoV-2 coreceptor protein, TMPRSS2, and experiments in
animal models raise the possibility that the most likely site of
peripheral lesion associated with the dysosmias in COVID-19 is
the sustentacular cell, a non-neuronal epithelial cell. Effects on
the CNS via the nasal mucosa cannot be discarded, and the
ACE2 transcriptomics show a remarkably wide distribution of
the receptor in many regions of the brain.
The second part of the review dissects hypothetical routes to
the CNS and other targets stemming from a much larger
receptive region, the apical plasmalemma of the intestinal
epithelial cell, the enterocyte. The intestinal mucosa is proposed
to be a preferred entry point, major viral reservoir, and favored
starting point for neurotropic routes that could be used by
SARS-CoV-2 upon binding to ACE2 and fusing to the
enterocyte’s apical membrane with the aid of TMPRSS2 and
TMRSS4. Examples of the correlation between these postulated
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Shiers, S., Wangzhou, A., Granados-Soto, V., Campbell, Z. T., Dussor,
G., and Price, T. J. (2020) Type I Interferons Act Directly on
Nociceptors to Produce Pain Sensitization: Implications for Viral
Infection-Induced Pain. J. Neurosci. 40 (18), 3517−3532.
(109) Harahsheh, A. S., Dahdah, N., Newburger, J. W., Portman, M.
A., Piram, M., Tulloh, R., McCrindle, B. W., de Ferranti, S. D., Cimaz,
R., Truong, D. T., and Burns, J. C. (2020)Missed or Delayed Diagnosis
of Kawasaki Disease During the 2019 Novel Coronavirus Disease
(COVID-19) Pandemic. J. Pediatr. 222, 261−262.
(110) Verdoni, L., Mazza, A., Gervasoni, A., Martelli, L., Ruggeri, M.,
Ciuffreda, M., Bonanomi, E., and D’Antiga, L. (2020) An outbreak of
severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2
epidemic: an observational cohort study. Lancet 395 (10239), 1771−
1778.
(111) Sachdeva, M., Gianotti, R., Shah, M., Bradanini, L., Tosi, D.,
Veraldi, S., Ziv, M., Leshem, E., and Dodiuk-Gad, R. P. (2020)
Cutaneous manifestations of COVID-19: Report of three cases and a
review of literature. J. Dermatol. Sci. 98 (2), 75−81.
ACS Chemical Neuroscience pubs.acs.org/chemneuro Review
https://dx.doi.org/10.1021/acschemneuro.0c00434
ACS Chem. Neurosci. 2020, 11, 2793−2803
2803
